Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950103-25-013417
Filing Date
2025-10-21
Accepted
2025-10-21 08:00:17
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4483
  Complete submission text file 0000950103-25-013417.txt   6739
Mailing Address NOVO ALLE DK 2880 BAGSVAERD DENMARK G7 00000
Business Address NOVO ALLE DK 2880 BAGSVAERD DENMARK G7 00000 4544448888
NOVO NORDISK A S (Filed by) CIK: 0000353278 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 117 AVENUE DE LUMINY BP 30191 MARSEILLE FRANCE France 13009
Business Address 117 AVENUE DE LUMINY BP 30191 MARSEILLE FRANCE France 13009 33430303030
Innate Pharma SA (Subject) CIK: 0001598599 (see all company filings)

EIN.: 000000000 | State of Incorp.: I0 | Fiscal Year End: 1231
LEI: 9695002Y8420ZB8HJE29
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91173 | Film No.: 251405386
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)